Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches that have drastically changed the course of the disease. In particular due to the high sensitivity of prostate cancer cells to hormone depletion, several agents able to inhibit hormone production or binding to nuclear receptor have been evaluated and adopted in clinical practice. However, despite several hormonal treatments being available nowadays for the management of advanced or metastatic prostate cancer, the natural history of the disease leads inexorably to the development of resistance to hormone inhibition. Findings regarding the mechanisms that drive this process are of particular and increasing interest as these are potentially related to the identification of new targetable pathways and to the development of new drugs able to improve our patients' clinical outcomes.
Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer / Mollica, Veronica; Di Nunno, Vincenzo; Cimadamore, Alessia; Lopez-Beltran, Antonio; Cheng, Liang; Santoni, Matteo; Scarpelli, Marina; Montironi, Rodolfo; Massari, Francesco. - In: CELLS. - ISSN 2073-4409. - 8:1(2019), p. 43. [10.3390/cells8010043]
Molecular Mechanisms Related to Hormone Inhibition Resistance in Prostate Cancer
Cimadamore, Alessia;Santoni, Matteo;Scarpelli, Marina;Montironi, Rodolfo;
2019-01-01
Abstract
Management of metastatic or advanced prostate cancer has acquired several therapeutic approaches that have drastically changed the course of the disease. In particular due to the high sensitivity of prostate cancer cells to hormone depletion, several agents able to inhibit hormone production or binding to nuclear receptor have been evaluated and adopted in clinical practice. However, despite several hormonal treatments being available nowadays for the management of advanced or metastatic prostate cancer, the natural history of the disease leads inexorably to the development of resistance to hormone inhibition. Findings regarding the mechanisms that drive this process are of particular and increasing interest as these are potentially related to the identification of new targetable pathways and to the development of new drugs able to improve our patients' clinical outcomes.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.